TMCnet News
Colorectal Cancer - Pipeline Review, H2 2016 - Therapeutics Assessment by Drug Target, MoA, RoA & Molecule Type - Research and MarketsResearch and Markets has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2016" report to their offering. Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal ancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned:
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/n4f5tf/colorectal_cancer View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005516/en/ |
